Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
…, L Wang, E De Stanchina, K Shien… - Proceedings of the …, 2012 - National Acad Sciences
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR-…
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR-…
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell–like properties in cancer cells
K Shien, S Toyooka, H Yamamoto, J Soh, M Jida… - Cancer research, 2013 - AACR
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) is a critical problem
in the treatment of lung cancer. Although several mechanisms have been shown to be …
in the treatment of lung cancer. Although several mechanisms have been shown to be …
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
K Shien, VA Papadimitrakopoulou, II Wistuba - Lung Cancer, 2016 - Elsevier
Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially
increase the efficacy of therapy for various malignancies, including non–small cell lung …
increase the efficacy of therapy for various malignancies, including non–small cell lung …
Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer
…, T Kubo, H Yamamoto, Y Maki, T Muraoka, K Shien… - Lung cancer, 2012 - Elsevier
Small-cell lung cancer (SCLC) is an aggressive tumor with a dismal prognosis among primary
lung cancers. MicroRNAs (miRNAs) can act as oncogenes or tumor-suppressor genes in …
lung cancers. MicroRNAs (miRNAs) can act as oncogenes or tumor-suppressor genes in …
Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
…, K Higasa, M Sakaguchi, K Shien… - Journal of the …, 2014 - academic.oup.com
We encountered a family of Japanese descent in which multiple members developed lung
cancer. Using whole-exome sequencing, we identified a novel germline mutation in the …
cancer. Using whole-exome sequencing, we identified a novel germline mutation in the …
Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy
K Shien, S Toyooka, K Ichimura, J Soh, M Furukawa… - Lung cancer, 2012 - Elsevier
The expression of several cancer stem cell (CSC)-related markers has been confirmed in
non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC…
non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC…
JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non–small cell lung cancer
K Shien, VA Papadimitrakopoulou, D Ruder… - Molecular cancer …, 2017 - AACR
Molecularly targeted drugs have yielded significant therapeutic advances in oncogene-driven
non–small cell lung cancer (NSCLC), but a majority of patients eventually develop …
non–small cell lung cancer (NSCLC), but a majority of patients eventually develop …
Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib
S Hashida, H Yamamoto, K Shien, Y Miyoshi… - Cancer …, 2015 - Wiley Online Library
Afatinib is an irreversible epidermal growth factor receptor ( EGFR )‐tyrosine kinase inhibitor
( TKI ) that is known to be effective against the EGFR T790M variant, which accounts for half …
( TKI ) that is known to be effective against the EGFR T790M variant, which accounts for half …
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells
K Namba, K Shien, Y Takahashi, H Torigoe… - Molecular Cancer …, 2019 - AACR
Upregulation of AXL is one of the mechanisms of acquired resistance to osimertinib, and
combination of osimertinib and cabozantinib might be a key treatment for overcoming …
combination of osimertinib and cabozantinib might be a key treatment for overcoming …
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
…, M Sakaguchi, K Shien, S Tomida, T Shien… - Cancer …, 2018 - Wiley Online Library
Compensatory activation of the signal transduction pathways is one of the major obstacles
for the targeted therapy of non‐small cell lung cancer (NSCLC). Herein, we present the …
for the targeted therapy of non‐small cell lung cancer (NSCLC). Herein, we present the …